Menu
Recruiting NCT02026843

Analysis of Biomarkers From Patients With Chorioretinal Diseases

Observational Diabetic Retinopathy Macular Degeneration

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Chorioretinal diseases.
Who it may be relevant to
Registry conditions: Diabetic Retinopathy, Macular Degeneration. Basic parameters: 20 years — 80 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
South Korea
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Overview

This study was conducted to investigate the levels of ocular biomarkers from the patients with chorioretinal diseases including diabetic retinopathy, retinal vascular diseases, age-related macular degeneration (dry and wet), and retinal degeneration.

Detailed description

This prospective, case-control study included 50 patients(50eyes) with chorioretinal diseases including diabetic retinopathy, retinal vascular diseases, age-related macular degeneration (dry and wet), and retinal degeneration. and 50 patient with nondiabetic retinopathy or cataract. Ocular fluids and blood samples were taken before injection of anti-vascular endothelial growth factor agent or pars plana vitrectomy for other retinal disease. Ocular biomarkers were analyzed.

Interventions

  • Drug Chorioretinal diseases
    chorioretinal diseases including diabetic retinopathy, retinal vascular diseases, age-related macular degeneration (dry and wet), and retinal degeneration

Primary outcome measures

  • Biomarkers in ocular fluids [Time frame: one month]

Eligibility criteria

Inclusion criteria

  • age over 20 years
  • patients requiring ophthalmologic treatments for different degrees of decreasing of visual acuity.
  • patients with chorioretinal diseases including diabetic retinopathy, retinal vascular diseases, age-related macular degeneration (dry and wet), and retinal degeneration.
  • control patients asking cataract surgery or vitrectomy for posterior segment nonproliferative disorders.

Exclusion criteria

  • under the age of 20 years
  • patients that received any anti-vascular endothelial growth factor agent for proliferative disease before taking sample of aqueous humor
  • patients that did not signed the informed consent of the trial
  • patients with intraocular inflammations or infections that requiring any pharmaceutical agent
  • patients with recent ocular trauma

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: Yes

Study design

Observational model
Case-control

Study locations

South Korea · 1 center
  • Dong Ho Park — Daegu

Identifiers

NCT: NCT02026843 · KNUH2013-1

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗